10-K: Pasithea Therapeutics Reports 2024 Annual Results, Highlights Clinical Progress of PAS-004

Pasithea Therapeutics' 2024 annual report details financial results and provides updates on the clinical development of PAS-004 and other pipeline programs.

Summary

• Pasithea Therapeutics, a clinical-stage biotechnology company, has released its annual report for the fiscal year ended December 31, 2024.
• The company is focused on developing innovative treatments for central nervous system (CNS) disorders and RASopathies.
• A key focus is the advancement of PAS-004, a next-generation MEK inhibitor, currently in a Phase 1 clinical trial.
• The FDA cleared the IND for PAS-004 in December 2023, and the Phase 1 trial is ongoing at multiple sites in the U.S. and Eastern Europe.
• The company plans to initiate a Phase 1/1b clinical trial of PAS-004 in adult NF1-PN patients in the first half of 2025.
• Pasithea is also developing PAS-003 for ALS and PAS-001 for schizophrenia, both in earlier stages of development.
• The company discontinued its PAS-002 program for MS and its support services to anti-depression clinics in 2023.
• Pasithea reported net losses of $13.9 million for 2024 and $16.0 million for 2023.
• As of December 31, 2024, the company had cash and cash equivalents of $6.9 million.
• The company expects research and development expenses to increase in 2025 due to ongoing and planned clinical trials for PAS-004.
• Pasithea will require additional capital to fund its operations and may seek to raise funds through equity offerings, debt financings, or collaborations.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While there is progress in clinical trials and development programs, the company's financial position raises concerns about its ability to continue as a going concern without additional funding.

Positives

• PAS-004 has received orphan-drug designation from the FDA for the treatment of NF1.
• The company successfully completed long-term chronic toxicology studies for PAS-004.
• Interim PK results from the Phase 1 study have demonstrated a half-life of approximately 60 hours for PAS-004.
• The company completed the development of a tablet formulation of PAS-004.
• The company has shown an upregulation of a 5 b 1 integrin in the human brain motor regions but not in sensory regions in ALS and that a 5 b 1 expression increases with disease progression in both mouse models of ALS and human ALS patients.

Negatives

• Pasithea has a limited operating history and has not generated any material revenue from product sales.
• The company has incurred net losses of approximately $13.9 million and $16.0 million for the years ended December 31, 2024 and 2023, respectively.
• The company has an accumulated deficit of approximately $49.6 million as of December 31, 2024.
• The company will need to raise additional capital to fund its operations.
• The company's auditor has included an explanatory paragraph regarding the company's ability to continue as a going concern.

Risks

• The company is dependent on the successful development and commercialization of PAS-004, which is not yet approved.
• Clinical trials are expensive, time-consuming, and difficult to design and implement, and involve an uncertain outcome.
• The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time consuming and inherently unpredictable.
• The commercial success of the company's product candidates, if approved, depends partially upon attaining market acceptance by physicians, patients, third-party payors, and the medical community.
• The company relies on third parties to conduct its clinical trials and manufacture its product candidates.
• The price of the company's Common Stock and Warrants may be volatile, and investors could lose all or part of their investment.
• The company may be negatively affected as a result of the actions of activists or hostile shareholders.

Future Outlook

The company expects research and development expenses to increase in fiscal year 2025 and plans to complete the FIH Phase 1 Dose Escalation Study in 2026. The company will need significant additional funds to meet operational needs and capital requirements for clinical trials, other research and development expenditures, and business development activities.

Industry Context

The report mentions competitors with FDA-approved MEK inhibitors, including GSK plc, Pfizer Inc., Genentech, Inc., AstraZeneca PLC and Merck & Co., Inc., and SpringWorks Therapeutics, Inc, indicating a competitive landscape in the development of treatments for NF1-PN and other indications. The company believes that Koselugo, Gomekli and other earlier generation MEK inhibitors approved for indications other than NFI suffer from limitations, such as known toxicities, high rates of drug discontinuation, limited efficacy and a dosing schedule that requires dosing twice a day.

Comparison to Industry Standards

• The company is developing PAS-004 as a next-generation MEK inhibitor to address the limitations of existing FDA-approved MEK inhibitors like Koselugo (selumetinib) and Gomekli (mirdametinib).
• Unlike FDA-approved MEK inhibitors, PAS-004 features a macrocyclic structure, a characteristic that we believe enhances potency, metabolic stability, and oral bioavailability.
• Preclinical studies showed that PAS-004 dosed at 5 mg/kg once daily reduced tumor volume similar to selumetinib dosed at 25mg/kg, twice daily, as published in Molecular Cancer Therapeutics in 2007.
• The company believes that the longer half-life of PAS-004, as compared to selumetinib, could potentially enhance efficacy by allowing more sustained MEK/ERK signaling inhibition.

Related Party Transactions

• In April 2023 we entered into a contract with PsychoGenics, Inc. (PsychoGenics) for the conduct of one of our preclinical studies. Dr. Emer Leahy, a member of our Board, is the current Chief Executive Officer and a less than 5% owner of PsychoGenics.
• The Steinman Consulting Agreement memorializes the compensation arrangements pursuant to which Prof. Steinman has been compensated for his services to our Company, as previously disclosed in our public filings.

Stakeholder Impact

• Shareholders face potential dilution from future equity offerings.
• Employees' job security is dependent on the company's ability to secure funding and continue operations.
• Patients may benefit from the development of new treatments for CNS disorders and RASopathies.
• Suppliers and creditors face potential risks if the company's financial situation deteriorates.

Next Steps

• Complete the first-in-human clinical trial of PAS-004.
• Advance clinical development of PAS-004 for NF1-PN.
• Expand utility of PAS-004 for other indications.
• Expand formulation development for PAS-004.
• Maximize the potential of discovery product candidates with selective use of business development and commercial collaborations.

Key Dates

Keywords

PAS-004, MEK inhibitor, NF1, ALS, Schizophrenia, Clinical trial, RASopathies, Biotechnology, FDA, Research and development, Financial results